Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 5Neoplasms 3Skin Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 24Nivolumab 9atezolizumab 8Drug Therapy 6cemiplimab 5Immune Checkpoint Inhibitors 5fludarabine 4Radiotherapy 4Paclitaxel 4Interleukin-2 4Cyclophosphamide 4Docetaxel 3fludarabine phosphate 2epacadostat 2durvalumab 2aldesleukin 2Taxes 2Radiosurgery 2Radiation 2Patient Reported Outcome Measures 2Oncolytic Virotherapy 2Ipilimumab 2Immunotherapy 2Gemcitabine 2Filgrastim 2Cisplatin 2Cetuximab 2Carboplatin 2vocimagene amiretrorepvec 1venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × sotigalimab × Dermatologic × Clear all
NCT02482168 2023-12-20

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡